Novartis: Sandoz to build plant in Slovenia
(CercleFinance.com) - Sandoz, a Novartis subsidiary, today announced that it has signed a memorandum of understanding to build a new biologics manufacturing facility in Lendava, Slovenia, to meet the growing global demand for biosimilar medicines.
Sandoz's investment is expected to be at least $400m.
Work on the new plant is expected to begin this year, with full operations tentatively scheduled for late 2026.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Sandoz's investment is expected to be at least $400m.
Work on the new plant is expected to begin this year, with full operations tentatively scheduled for late 2026.
Copyright (c) 2023 CercleFinance.com. All rights reserved.